This NDC is on FDA's drug shortage list (posted Mar 10, 2023)
Product Information
CLONAZEPAM 1 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.0244 per EA under NDC 72888015305. Its NADAC has been published 175 times since May 31, 2023.
FDA first approved this application on Oct 6, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888015305
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA075468FDA Approved
10/6/2000
TE Code
AB
On Market Since
4/14/2022
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 1 MG TABLET has been published 175 times since May 31, 2023, and over the history we have for it it has declined 26.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0244 per EA |
|---|---|
| All-time high | $0.0342 (Sep 13, 2023) |
| All-time low | $0.0244 (Sep 23, 2026) |
| 52-week high | $0.0285 |
| 52-week low | $0.0244 |
| Median price | $0.0294 |
| Average price | $0.0289 |
| Largest weekly change | +23.6% (Jun 19, 2024) |
| Weeks tracked | 175 |
| Tracking since | May 31, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clonazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 1 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.0244 per EA (NDC 72888015305), effective Sep 30, 2026.
How has the price of CLONAZEPAM 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 1 MG TABLET has declined 26.0%. It has been tracked across 175 weekly CMS publications since May 31, 2023.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 1 MG TABLET?
Since May 31, 2023, the NADAC for CLONAZEPAM 1 MG TABLET has ranged from a low of $0.0244 (Sep 23, 2026) to a high of $0.0342 (Sep 13, 2023), with a median of $0.0294 per EA.
Are there cheaper alternatives to CLONAZEPAM 1 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLONAZEPAM 1 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CLONAZEPAM 1 MG TABLET?
CLONAZEPAM 1 MG TABLET (NDC 72888015305) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.
Is CLONAZEPAM 1 MG TABLET in shortage?
Yes — NDC 72888015305 is currently listed in FDA's drug shortage database (posted Mar 10, 2023).